Достижение контроля над бронхиальной астмой и изменение качества жизни пациентов при терапии отечественным комбинированным препаратом Биастеном

The aim of the study was to assess abilities for achieving the control of the disease and to improve quality of life in moderate bronchial asthma using the Russian combined drug Biasten (“Pulmomed”) containing budesonid and salbutamol hemisuccinate. A comparative randomized open study involved 43 patients with moderate uncontrolled bronchial asthma (13 men and 30 women), of them 22 patients were treated with Biasten 2 inhaled doses twice a day, and 22 patients received equal doses of Benacort (budesonid) and Salben (salbutamol) during 12 weeks. Dynamics of clinical symptoms, peak flowmetry and flow-volume curve parameters, and daily need in β 2 -agonists were evaluated during the treatment. Quality of life was assessed using the AQLQ questionnaire. Results demonstrated high clinical efficacy, safety, possibility of optimal asthma control, and improvement in quality of life in moderate asthmatic patients while taking the combined drug Biasten.